The Technical Analyst
BioLineRx Ltd. [BLRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BioLineRx Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.74% $0.613
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 52.09 mill |
| EPS: | -0.900 |
| P/E: | -0.680 |
| Earnings Date: | May 22, 2024 |
| SharesOutstanding: | 84.98 mill |
| Avg Daily Volume: | 0.424 mill |
| RATING 2024-04-24 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.680 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.12x |
| Company: PE -0.680 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.344 (-43.82%) $-0.269 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.507 - 0.719 ( +/- 17.29%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.610
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.610
Forecast 2: 16:00 - $0.610
Forecast 3: 16:00 - $0.610
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.613 (-3.74% ) |
| Volume | 0.759 mill |
| Avg. Vol. | 0.424 mill |
| % of Avg. Vol | 178.99 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BLRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BLRX
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Latest Press Releases
2024-04-17 07:00:00 - Press Release
Biolinerx Announces Poster Presentation On Apheresis Center Efficiency And Cxcr4 Antagonists Including Aphexda® (motixafortide) In Patients With Multiple Myeloma At The Asfa 2024 Annual Meeting
Tel aviv, israel , april 17, 2024 /prnewswire/ -- biolinerx ltd. (nasdaq: blrx) (tase: blrx), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and cxcr4 antagonists including aphexda (motixafortide) in patients with multiple myeloma.
2024-04-01 09:00:00 - Press Release
Biolinerx Announces $6 Million Registered Direct Offering
Tel aviv, israel , april 1, 2024 /prnewswire/ -- biolinerx ltd. (nasdaq: blrx) (tase: blrx) ("biolinerx" or the "company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the company's american depositary shares (adss) and warrants to purchase up to an aggregate of 7,500,000 adss, at a combined purchase price of $0.80 per ads and accompanying warrant.
2024-03-26 07:00:00 - Press Release
Biolinerx Reports 2023 Financial Results And Recent Corporate And Portfolio Updates
- reported significant commercial progress for aphexda® -- secured payer coverage representing ~95% of covered lives in the u.s.; continued progress on formulary approvals at targeted major transplant centers; r eceived healthcare common procedure coding system (hcpcs) j-code to facilitate medicare reimbursement - - announced first patient dosed in randomized phase 2b clinical trial evaluating motixafortide in first-line pancreatic cancer - - continued to support partner gloria biosciences in plans to execute pivotal bridging study of motixafortide in stem cell mobilization and phase 2b randomized study in first-line pancreatic cancer in china - - management to host conference call today, march 26, at 8:30 am edt - tel aviv, israel , march 26, 2024 /prnewswire/ -- biolinerx ltd...
2024-02-28 07:00:00 - Press Release
Biolinerx Announces First Patient Dosed In Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide In First-line Pancreatic Cancer (pdac)
- conducted in collaboration with columbia university, the chemo4metpanc phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a pd-1 inhibitor and first-line pdac chemotherapies compared to chemo alone - - gulam manji, md, phd, of columbia university to present encore pilot phase data at the immuno-oncology (io) 360° summit on february 29 - tel aviv, israel , feb. 28, 2024 /prnewswire/ -- biolinerx ltd. (nasdaq: blrx) (tase: blrx), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the first patient has been dosed in the randomized chemo4metpanc phase 2 combination clinical trial evaluating the company's cxcr4 inhibitor motixafortide, the pd-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (pdac).
2024-02-16 07:00:00 - Press Release
Biolinerx Announces Acceptance Of Two Poster Presentations On Aphexda® (motixafortide) For Cd34+ Hematopoietic Stem Cell (hsc) Mobilization In Patients With Multiple Myeloma At The 2024 Tandem Meetings Of Astct® And Cibmtr®
Results include pharmacokinetic and pharmacodynamic data, and post-hoc subgroup analyses of the phase 3 genesis trial presentations on thursday, february 22, 2024 in san antonio, texas tel aviv, israel , feb. 16, 2024 /prnewswire/ -- biolinerx ltd. (nasdaq/tase: blrx), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new post-hoc subgroup analyses and pharmacodynamic data will be presented on aphexda® (motixafortide) for cd34+ hematopoietic stem cell (hsc) mobilization in patients with multiple myeloma at the 2024 tandem meetings: transplantation & cellular therapy meetings of the american society for transplantation and cellular therapy (astct®) and the center for international blood and marrow transplant research (cibmtr®), taking place february 21-24, 2024, in san antonio, texas.
Latest News
2024-02-25 14:12:12 - InvestorPlace
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
In almost every situation, investors should stay away from penny stocks. They're extremely speculative and they tend to facilitate delusions of grandeur.
2023-12-04 18:42:54 - Seeking Alpha
BioLineRx: Still A Buy, With Some Questions
BioLineRx gains approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination with other treatments for pancreatic cancer. Financially, BioLineRx has a limited amount of cash on hand but has secured a licensing deal that provides additional funds.
2023-12-02 23:25:30 - Seeking Alpha
BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges
BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma patients. BioLineRx's low cash reserves and need for additional financing pose risks, but its valuation appears relatively conservative.
2023-11-20 13:54:04 - Seeking Alpha
BioLineRx Ltd. (BLRX) Q3 2023 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2023 Earnings Conference Call November 20, 2023 10:00 PM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Conference Call Participants Joe Pantginis - H.C.
2023-11-02 15:12:42 - InvestorPlace
3 Tech Stocks That Wall Street Loves More Than Nvidia
The future of the U.S. economy appears to be at a pivotal juncture as the Federal Reserve maintains interest rates at a 22-year high, with the possibility of further tightening on the horizon. Despite strong economic indicators, including a robust labor market and faster-than-expected GDP growth, the central bank remains cautious about achieving its 2% inflation target.
2023-10-30 11:38:06 - InvestorPlace
3 Top Penny Stocks to Make You a Millionaire in 5 Years
In general, penny stock investing is all about quick gains. Investors in this high-risk world usually are in it for a quick buck.
2023-09-18 12:55:34 - PennyStocks
3 Hot Penny Stocks To Watch Before The September Fed Meeting
Penny stocks represent an exciting yet risky path to profits for active investors. Defined as stocks priced under $5 per share, these cheap equities boast the potential for astronomical returns on minimal investments.
2023-09-18 01:28:37 - Seeking Alpha
Assessing BioLineRx As A Buy After Drug Approval
BioLineRx has received approval for their stem cell mobilizing compound, motixafortide, for certain forms of blood cancer. The compound has shown impressive results in mobilizing stem cells in patients, with a high success rate in optimal stem cell collection. However, there are concerns about competition from generic versions of a similar drug and the decreasing need for immediate autologous transplants in patients with multiple myeloma.
2023-09-11 09:58:51 - Proactive Investors
BioLineRx rallies on FDA approval of Aphexda with Filgrastim
Bioline RX Ltd (NASDAQ:BLRX) shares jumped at the market open on Monday after the US Food and Drug Administration approved the use of Aphexda (motixafortide) in combination with filgrastim for patients with multiple myeloma, a type of bone marrow cancer. The company's Nasdaq-listed shares rose as much as 23% in pre-market trading before opening 10% higher at $2.33.
2023-08-07 14:34:09 - InvestorPlace
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
One of the safest sectors on the market is biotech. After all, we can't stop people from aging — at least not yet.